Pharmacokinetic and pharmacodynamic drug–drug interaction assessment between pradigastat and digoxin or warfarin

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of clinical pharmacology

• Publication date

  2014-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcph.285PMID 24619917
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suitability of digoxin as a P‐glycoprotein probe: Implications of other transporters on sensitivity and specificity

  2014cited by this paper
• The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype.

  2013cited by this paper
• The DGAT1 inhibitor Pradigastat Decreases Chylomicron Secretion and Prevents Postprandial Triglyceride Elevation in Humans

  2013cited by this paper
• The DGAT1 Inhibitor LCQ908 Decreases Triglyceride Levels in Patients with the Familial Chylomicronemia Syndrome

  2012cited by this paper
• Multiple Doses of Sitagliptin, a Selective DPP‐4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin

  2009cited by this paper
• CENTER FOR DRUG EVALUATION AND RESEARCH

  2007cited by this paper
• Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers

  2007cited by this paper
• Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat

  2000cited by this paper
• Plasma protein binding displacement interactions--why are they still regarded as clinically important?

  1994cited by this paper
• Biliary excretion studies with digoxin in man.

  1977cited by this paper

• Computational Identification of Phytochemical Inhibitors Against White Spot Syndrome Virus dUTPase: A Potential Antiviral Approach

  2025cites this paper
• The influence of Javanese turmeric (Curcuma xanthorrhiza) on the pharmacokinetics of warfarin in rats with single and multiple-dose studies

  2021cites this paper
• Strategy for the Prediction of Steady-State Exposure of Digoxin to Determine Drug–Drug Interaction Potential of Digoxin With Other Drugs in Digitalization Therapy

  2019cites this paper
• Clinical Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase 1 Inhibitor

  2017cites this paper
• Pradigastat disposition in humans: in vivo and in vitro investigations

  2017cites this paper
• Triglyceride-lowering trials

  2017cites this paper
• The Fluorine Atom in Health Care and Agrochemical Applications: A Contribution to Life Science

  2017cites this paper
• Assessment of pharmacokinetic drug‐drug interaction between pradigastat and atazanavir or probenecid

  2016cites this paper
• The DGAT1 inhibitor pradigastat does not induce photosensitivity in healthy human subjects: a randomized controlled trial using three defined sunlight exposure conditions

  2016cites this paper
• The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life

  2016cites this paper
• Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on the pharmacokinetics of a combination oral contraceptive in healthy female subjects.

  2015cites this paper
• Assessment of Drug Interaction Potential between LCZ696, an Angiotensin Receptor Neprilysin Inhibitor, and Digoxin or Warfa rin

  2015cites this paper
• Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor

  2015influential citation
• Assessment of pharmacokinetic drug-drug interaction between pradigastat and acetaminophen in healthy subjects

  2015cites this paper
• Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome

  2015cites this paper
• Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.

  2015cites this paper
• Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor

  2015influential citation
• Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin

  2015cites this paper
• Evaluation of food effect on the oral bioavailability of pradigastat, a diacylglycerol acyltransferase 1 inhibitor

  2015influential citation
• Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug–drug interaction with ketoconazole

  2014cites this paper